close
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Apellis Pharmaceuticals, Inc. - Common Stock (NQ:APLS)

19.73 -0.37 (-1.84%)
Streaming Delayed Price Updated: 4:00 PM EST, Nov 18, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Apellis Pharmaceuticals, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
19 20 Next >
News headline image
What's Going With Apellis Pharmaceuticals Stock Friday? ↗
Apellis Pharmaceuticals shares are moving lower after the Committee for Medicinal Products for Human Use of the European Medicines Agency confirmed its June 2024 negative opinion following... 
Via Benzinga
News headline image
Apellis Stock Hammered After Eye Drug Gets A Third European Rejection ↗
The company is "out of European approval options" for its embattled geographic atrophy drug, says one analyst. 
Via Investor's Business Daily
News headline image
Apellis Receives Negative CHMP Opinion for Pegcetacoplan for Geographic Atrophy (GA) in the EU Following Re-Examination
From Apellis Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Analyst Scoreboard: 15 Ratings For Apellis Pharmaceuticals ↗
 
Via Benzinga
News headline image
Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Apellis Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Critical Insights From Apellis Pharmaceuticals Analyst Ratings: What You Need To Know ↗
 
Via Benzinga
News headline image
Peeling Back The Layers: Exploring Apellis Pharmaceuticals Through Analyst Insights ↗
 
Via Benzinga
News headline image
Apellis Pharmaceuticals to Present at Upcoming Investor Conferences
From Apellis Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Wedbush Just Raised its Price Target on These 7 Stocks: August 12, 2024 ↗
New Wedbush price targets have been issued for each of the following seven stocks, including a few that may come as a surprise to some. 
Via InvestorPlace
News headline image
Apellis Pharmaceuticals' Pegcetacoplan Meets Primary Goal In Late-Stage Study In Patients With Rare Kidney Diseases ↗
Swedish Orphan Biovitrum and Apellis Pharmaceuticals released topline results from the Phase 3 VALIANT study of pegcetacoplan for C3 glomerulopathy and IC-MPGN. The study met primary and secondary... 
Via Benzinga
News headline image
Apellis and Sobi Announce Positive Topline Results from Phase 3 VALIANT Study of Pegcetacoplan in C3G and Primary IC-MPGN
From Apellis Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
What Analysts Are Saying About Apellis Pharmaceuticals Stock ↗
 
Via Benzinga
News headline image
Expert Outlook: Apellis Pharmaceuticals Through The Eyes Of 15 Analysts ↗
 
Via Benzinga
News headline image
In-Depth Examination Of 14 Analyst Recommendations For Apellis Pharmaceuticals ↗
 
Via Benzinga
News headline image
Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Apellis Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Apellis Pharmaceuticals Reports Second Quarter 2024 Financial Results
From Apellis Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Apellis Pharmaceuticals to Host Conference Call on August 1, 2024, to Discuss Second Quarter 2024 Financial Results
From Apellis Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Apellis Announces Five Abstracts Accepted for Oral Presentation at the American Society of Retina Specialists (ASRS) Annual Scientific Meeting
From Apellis Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Nike, Accolade And Other Big Stocks Moving Lower In Friday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Apellis Plans to Seek Re-Examination Following Negative CHMP Opinion for Pegcetacoplan for Geographic Atrophy (GA) in the EU
From Apellis Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
SYFOVRE® (pegcetacoplan injection) Preserved Visual Function at 36 Months in GALE Extension Study in Geographic Atrophy (GA)
From Apellis Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Apellis Pharmaceuticals to Host a Fireside Chat at the Goldman Sachs 45th Annual Global Healthcare Conference
From Apellis Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Positive One-Year Data from Phase 2 Study of Pegcetacoplan in Post-Transplant Recurrence of C3G and IC-MPGN Presented as Late-Breaker at ERA Congress
From Apellis Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Apellis Pharmaceuticals Refinances Existing Debt with Up to $475 Million Non-Dilutive Credit Facility from Sixth Street
From Apellis Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
APLS Stock Earnings: Apellis Pharmaceuticals Misses EPS, Beats Revenue for Q1 2024 ↗
APLS stock results show that Apellis Pharmaceuticals missed analyst estimates for earnings per share but beat on revenue for the first quarter of 2024. 
Via InvestorPlace
News headline image
Apellis Pharmaceuticals Reports First Quarter 2024 Financial Results
From Apellis Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Apellis Pharmaceuticals to Host a Fireside Chat at the Bank of America Securities Healthcare Conference
From Apellis Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Apellis Announces 11 Oral Presentations at the Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting
From Apellis Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Apellis Announces Pegcetacoplan MAA Review Has Been Reset to Day 180 of Initial Assessment by European Medicines Agency (EMA)
From Apellis Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Apellis Pharmaceuticals to Host Conference Call on May 7, 2024, to Discuss First Quarter 2024 Financial Results
From Apellis Pharmaceuticals, Inc.
Via GlobeNewswire
< Previous 1 2 3 4 5 6 7 8 9
...
19 20 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Starting at $3.75/week.

Subscribe Today